Peptide Therapeutics Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 52.59 Bn

Forecast Year, 2035

USD 87.21 Bn

CAGR, 2026 - 2035

5.19%

Report Coverage

Global

What is the Peptide Therapeutics Market Size?

The global peptide therapeutics market size is calculated at USD 52.59 billion in 2025 and is predicted to increase from USD 56.06 billion in 2026 to approximately USD 87.21 billion by 2035, expanding at a CAGR of 5.19% from 2026 to 2035. The peptide therapeutics market growth is driven by an increasing prevalence of cancer and other metabolic diseases.

Peptide Therapeutics MarketKey Takeaways

• North America dominated the market with the highest market share of 45.96% in 2025.
• Asia Pacific is projected to expand at the fastest CAGR of 6.20% between 2026 and 2035.
• By application, the metabolic disorder segment has captured around 22.80% of the market share in 2025.
• By application, the gastrointestinal disorder segment is poised to grow at a CAGR of 6.31% between 2026 and 2035.
• By type, the innovative segment has accounted for more than 60.40% of revenue share in 2025.
• By type, the generic segment is expected to expand at a notable CAGR of 4.76% between 2026 and 2035.
• By route of administration, the parenteral segment has generated more than 76.03% of revenue share in 2025.
• By route of administration, the oral segment is expanding at a CAGR of 6.02% between 2026 and 2035.
• By distribution channel, the hospital pharmacies segment has contributed around 39.90% of the market share in 2025.
• By distribution channel, the online drug stores segment is projected to grow at a CAGR of 5.51% between 2026 and 2035.
• By synthesis technology, the liquid phase peptide synthesis (LPPS) segment has recorded the largest market share of 45.87% in 2025.

Market Overview

Naturally occurring peptides are strings of amino acids present in all living organisms. Peptide therapeutics are used for the treatment of various diseases. Peptides act as anti-infective growth hormones and even serve as ion channel ligands. Peptide therapeutics are capable of performing the same functions.

The development in biotech and pharmaceutical industries worldwide has proven that peptide therapeutics can stimulate essential hormones. With growing age, peptide production in the human body is disrupted. Peptide therapeutics safely and effectively reintroduce vital peptides into the body.

Peptide therapeutics treat neurological issues, diabetes, cancer, heart issues, and numerous other diseases. Moreover, peptide therapeutics offer muscle endurance, pain relief, injury recovery, and help in weight loss. Peptides are directly delivered into the bloodstream during the therapy. Peptide therapeutics have advanced rapidly in the pharmaceutical and biotech industries. Peptide therapeutics have gained popularity in the global nutrition industry in recent years.

Furthermore, the healthcare sector across the globe has adopted the peptide drug delivery option rapidly. Peptide therapeutics have positively impacted human health by improving stamina and immunity and reducing undesired side effects caused by prolonged chronic diseases.

What is the Role of AI in the Peptide Therapeutic Market?

The key benefit of artificial intelligence (AI) algorithms can also improve the synthesis process by predicting the most efficient and cost-effective routes for peptide synthesis. The main benefit of using peptides in therapies is their ability to minimize the impact on healthy cells, allowing for targeted action directly on tumor cells. AI is used in addiction treatment to personalize care plans, predict relapse risks, analyze patient data, and automate administrative tasks. AI systems can identify patterns in behavior and treatment responses, helping clinicians provide tailored interventions that increase the likelihood of successful recovery.

AI in peptide therapeutics includes that we can access an AI therapist chatbot 24/7 with no wait times. AI therapy may be an easier entry point for those who are hesitant to see a therapist, and it is offered at a lower cost compared to human therapy. AI has the potential to transform drug discovery by improving data analysis and prediction, leading to faster and more effective treatments.

Market Trends

• Technological innovation in peptide therapeutics
• Rising investment in R&D of new drugs
• Increasing incidences of metabolic diseases
• Rising prevalence of cancer

Market Scope

Market Dynamics

Driver

Increasing incidences of metabolic disorders:

Peptide drug application in metabolic disorders and discovery strategies. All life activities are dependent on metabolic homeostasis, which is maintained by many biological pathways in the body. In recent years, many peptide drugs for metabolic disorders treatment have become blockbusters in the pharmaceutical market. Metabolic peptides can influence metabolic processes and contribute to both inflammatory and anti-inflammatory responses.

Restraint

High cost of drug development:

The high cost of a drug is an expensive prescribed item and represents an inappropriate cost relative to the total cost of the relevant episode in terms of volume and cost. The high cost of drug development is challenging for an industry being pressured to cut costs. It makes it harder to advance new ideas and create new cures. The cost of the medical product to the market has been increasing, and clinical trials constitute a large portion of these costs.

Opportunity

Expansion of minimally invasive therapies:

The minimally invasive therapies' benefits include visible scars that are smaller and fewer, reduced costs, quicker return to work, less need for narcotics, fewer respiratory complications, lower bleeding, improved surgical accuracy, decreased risk of muscle damage, accurate procedures, minimal scarring, improved cosmetic outcomes, smaller incisions, lower complication rates, less tissue trauma, faster recovery, reduced blood loss, less scarring, shorter hospital stays, lower risk of infection, and less pain.

Segment Insights

Application Insights

Why Are There Increases in Demand for Metabolic Disorders?

Metabolic disorder segment has dominated the market in 2025, with the growth of diabetes and obesity. High specificity and safety profile provided by peptide medicines provide effective management of diabetes and obesity for an extended period of time. Thus, there will be an increase in demand for peptide-based therapies for both inpatient and outpatient settings.

The fastest-growing application for peptide-based therapies is the GI disorders. There has been a substantial increase in diagnosis of inflammatory bowel disease and functional GI disorders. The increase in stability and ability to deliver peptides to specific locations are producing better patient outcomes via quicker adoption in clinical practice and the development of new peptide-based therapies.

Peptide Therapeutics Market Revenue (USD Million), By Application, 2022-2024

Type Insights

Why Are Innovative Peptides Dominating the Market in 2025?

Innovative peptide-based therapeutics are dominating due to strong effectiveness demonstrated in the clinical setting, innovative mechanisms of action, and substantial investment in research and development. The availability of innovative peptide-based therapies provides a very effective way to treat chronic diseases at a higher price than traditional therapies; therefore, the revenue produced from manufacturing innovative peptides will continue to be significant in the developed world.

The fastest growing type of peptide-based therapeutics is the generic version. As patents expire and manufacturing technology improves, the cost of manufacturing generic peptides will decline significantly; therefore, more and more health systems will begin to use generic peptide-based therapeutics for cost-sensitive populations and long-term treatment regimens.

Route of Administration Insights

Which Route of Administration Dominated the Market in 2025?

Parenteral administration of peptide drugs dominated the peptide therapeutics market because they have the greatest degree of bioavailability, and their dosages can be accurately measured or specified. For many peptides that would be degraded following oral administration, thus, injections will remain the preferred method of administration in treating patients with cancer, metabolic diseases, and autoimmune diseases.

The oral route of administration for peptide drugs is fastest growing segment. Improvements in the stability of peptide drugs, the addition of permeability enhancers to the formulations for these drugs, and the increasing number of patients seeking to avoid invasive treatments will result in a dramatic rise in the number of peptide drugs being administered through the oral route of administration in the near future.

Peptide Therapeutics Market Revenue (USD Million), By Route of Administration, 2022-2024

Distribution Channel Insights

Hospital pharmacies dominate the distribution channels for peptide therapies because the highest utilization of peptide therapies occurs in hospitals under both inpatient and specialty care settings. The complexity of the required administration and physician oversight of therapy for patients receiving chronic and critical care must also be addressed in the hospital pharmacy setting.

Online pharmaceutical retailers have become the fastest-growing Distribution Channel through the adoption of digital health technology and improvements in cold chain logistics. Due to the preference of patients for receiving their medications at home and the increased accessibility of chronic medications to patients, the fastest-growing Distribution Channel for peptide therapies is on a global basis.

Synthesis Technology Insights

Why Liquid Phase Synthesis Has a Very Large Market Share?

Liquid-phase synthesis of peptides dominates the peptide manufacturing market because it can produce large volumes of high-quality (pure) peptides needed to produce long and/or complex peptide chains at a reasonable (high) yield. Liquid phase-synthesized peptides are most often used in the commercial production of biotechnology-based pharmaceuticals.

Solid-phase-synthesized peptides are gaining popularity due to increased automation in the solid-phased synthesis process, resulting in shorter production schedules and better efficiencies. The continued use of solid-phase-synthesized peptides in the research arena (as a result of the growing popularity of small batch production) will greatly facilitate the growth of solid-phase-synthesized peptides in future years.

Regional Insights

U.S. Peptide Therapeutics Market Size and Forecast 2026 to 2035

The U.S. peptide therapeutics market size is estimated at USD 21.24 billion in 2025 and is anticipated to reach around USD 34.98 billion by 2035, with a CAGR of 5.12% from 2026 to 2035.

North America led the global peptide therapeutics market and captured more than 45.96% of the revenue share in 2025. The market's growth in North America is attributed to the rising demand for peptide drug products to treat cancer in the region.

The development of the biotechnology and pharmaceutical industries has fueled market growth in North America. Europe shows potential market growth for peptides in the region. The well-established healthcare industry in Europe is considered a significant factor in the development of the market. However, high-priced peptide drugs in Europe hamper the growth of the market.

U.S.

Due to its strong biopharmaceutical industry, significant investment in new therapy development and large number of peptide-focused biopharma companies and contract manufacturers supporting research and large-scale production has given the United States the lead in the North American peptide therapeutic market. The increasing use of peptide products in oncology, endocrinology, and infectious diseases is fueling demand for peptides in clinical practice. Comprehensive reimbursement policies, cutting-edge clinical trial capabilities and ongoing government support for novel therapies help accelerate the use of peptides in therapeutics. Coupled with sustained patient access to specialty medications, this ensures the United States will continue to be the leader in the peptide therapeutic market for many years to come.

Asia Pacific is anticipated to witness significant growth during 2026-2035. The rising prevalence of diabetes and infectious diseases is a driving factor for developing the market in the Asia Pacific. Developing the healthcare and biotech sectors in India and China is considered to fuel the demand for peptide drugs in the upcoming years. The growth of the peptide therapeutics market in the Asia Pacific is driven because of the availability of low-cost raw materials in the region.

The rising development of novel peptide drugs for treating respiratory disorders and increasing investments in R&D activities propel the growth of the peptide therapeutics market in Latin America. Brazil is expected to dominate the peptide therapeutics market owing to the country's increased number of peptide therapies. Moreover, rapid adoption and increased awareness of peptide therapies in the Middle East and Africa will boost the demand for peptide therapeutics in these regions during the forecast period.

• In February 2025, to expand peptide therapeutics and CDMO capabilities, Granules India signed an acquisition agreement with a Switzerland-based Senn Chemicals AG, a contract development and manufacturing organization (CDMO) specializing in peptides. The acquisition, expected to close in the first half of 2025, is subject to specific conditions. (Source: expresspharma.in )

China

Expanding biotech industry in China and government's support for new drug therapies positioned China as the leader in the Asia Pacific peptide therapeutic marketplace. Rapid growth in research, manufacturing and clinical application of peptides is occurring within China. Additionally, the rising prevalence of cancer, diabetes and hormonal disorders is causing a significant increase in the number of peptide therapies needed. Improvements in regulatory efficiencies and the increased capability of domestic pharmaceutical companies to manufacture peptide therapies is allowing for an increase in new product introductions, solidifying China's role as an important factor in the regional market expansion for peptide therapeutics.

What Latin America Presents Early Market Opportunity?

Latin America represents an emerging area in peptide therapeutics as improvements in healthcare infrastructure and improved access to advanced medicines are progressing steadily. Due to increases in the rate of occurrence of chronic diseases like diabetes and cancer, the need for more effective and directed therapy has increased significantly. In addition to the investment in modern treatment modalities such as biologics and peptide therapy by governmental and non-governmental healthcare providers, there is currently looking to be further market potential based on increased awareness among healthcare providers coupled with expanding the modalities of pharmaceutical supply networks. Reforms in healthcare might also have an impact on continued expansion of the market.

Brazil

Brazil is the predominant leader of the peptide therapeutics marketplace in Latin America, as it has the largest number of patients and is one of the countries with the most developed healthcare systems in this region. As a country, Brazil has been moving toward adopting more innovative therapeutics in endocrinology and oncology. Private healthcare facilities are increasing across Brazil, specifically due to pharmaceutical investment. In Brazil, the focus on the local manufacture of pharmaceuticals and the development of clinical research opportunities will further assist the development of Brazil in the regional marketplace of peptide therapy.

How Middle East Africa Gains Momentum in Peptide Therapeutics Market?

The Middle East and Africa are experiencing rapid growth within their peptide drug markets due to increasing investment into the healthcare industry and improvement in overall health care availability, as well as a higher rate of metabolic disorders, cancers, and rare diseases. Several countries are further investing in their healthcare systems by developing hospitals, which support the introduction of specialty drugs. The establishment of partnerships with international pharmaceutical companies, slow regulatory changes, and increasing access to specialty care facilities are providing additional support for peptide drug usage.

Saudi Arabia

Saudi Arabia currently has the largest peptide therapeutics market within the Middle East and Africa because of its investment in healthcare-related infrastructure and the continuing trend toward advanced treatment options. Through national health programs and hospital modernization, Saudi Arabia is creating greater access to specialty medicines through hospitals; thus there is a growing demand for innovative therapy and an increased level of cooperation between global pharmaceutical companies with respect to the introduction of peptide-based therapies; therefore, Saudi Arabia should continue on its path to be one of the fastest-growing areas within the region.

Peptide Therapeutics Market Companies

• Eli Lilly & Company
• Amgen Inc.
• Pfizer, Inc.
• Ever Neuro Pharma GmbH
• Bausch Health
• Abbvie

Segments Covered in the Report

By Application

• Gastrointestinal Disorder
• Metabolic Disorder
• Neurological Disorder
• Cancer
• Others

By Type

• Generic
• Innovative

By Route of Administration

• Oral
• Parenteral
• Pulmonary
• Mucosal
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Drug Stores

By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

ByGeography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa